1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the transaction
|
The sale of 9,000 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.7189
|
9,000
|
||
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications & CEO Office
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the transaction
|
The sale of 4,340 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.7944
|
4,340
|
||
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dylan Jackson
|
|
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the transaction
|
The sale of 13,616 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6871
|
13,616
|
||
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Dylan Jackson
|
|
b)
|
Position/status
|
PCA of Sally Jackson (SVP, Global Communications & CEO
Office)
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB0009252882
|
|
b)
|
Nature of
the transaction
|
The sale of 2,476 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.7145
|
2,476
|
||
d)
|
Aggregated information
Aggregated volume Price
|
N/A (single transaction)
|
|
e)
|
Date
of the transaction
|
2024-03-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, GSK Global Health
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
The sale of 60,000 Ordinary Shares
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.8004
|
60,000
|
||
d)
|
Aggregated
information
|
N/A (single transaction)
|
|
Aggregated
volume Price
|
|
||
e)
|
Date
of the transaction
|
2024-03-12
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Emma Walmsley
|
|
b)
|
Position/status
|
Chief Executive Officer
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
7
(partnership shares)
|
||
£16.6610
|
7
(matching shares)
|
||
d)
|
Aggregated
information
|
||
Aggregated
volume Price
|
14 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Julie Brown
|
|
b)
|
Position/status
|
Chief Financial Officer
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
8 (partnership shares)
|
||
£16.6610
|
8 (matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
James Ford
|
|
b)
|
Position/status
|
SVP and Group General Counsel, Legal and Compliance
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
8 (partnership shares)
|
||
£16.6610
|
8 (matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Sally Jackson
|
|
b)
|
Position/status
|
SVP, Global Communications and CEO Office
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
7
(partnership shares)
|
||
£16.6610
|
7
(matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
David Redfern
|
|
b)
|
Position/status
|
President Corporate Development
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
8
(partnership shares)
|
||
£16.6610
|
8
(matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Regis Simard
|
|
b)
|
Position/status
|
President, Global Supply Chain
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
8
(partnership shares)
|
||
£16.6610
|
8
(matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Philip Thomson
|
|
b)
|
Position/status
|
President, Global Affairs
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
8 (partnership shares)
|
||
£16.6610
|
8 (matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
16 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Deborah Waterhouse
|
|
b)
|
Position/status
|
CEO, ViiV Healthcare and President, Global Health, GSK
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
7
(partnership shares)
|
||
£16.6610
|
7
(matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
1.
|
Details of PDMR/person closely associated with them
('PCA')
|
||
a)
|
Name
|
Victoria Whyte
|
|
b)
|
Position/status
|
Company Secretary
|
|
c)
|
Initial
notification/ amendment
|
Initial notification
|
|
2.
|
Details of the issuer, emission allowance market participant,
auction platform, auctioneer or auction monitor
|
||
a)
|
Name
|
GSK plc
|
|
b)
|
LEI
|
5493000HZTVUYLO1D793
|
|
3.
|
Details of the transaction(s): section to be repeated for (i) each
type of instrument; (ii) each type of transaction; (iii) each date;
and (iv) each place where transaction(s) has been
conducted
|
||
a)
|
Description
of the financial instrument
|
Ordinary shares of 31 ¼ pence each ('Ordinary
Shares')
ISIN: GB00BN7SWP63
|
|
b)
|
Nature
of the transaction
|
Acquisition of Ordinary Shares under the Company's Share Reward
Plan
|
|
c)
|
Price(s)
and volume(s)
|
Price(s)
|
Volume(s)
|
£16.6610
|
7
(partnership shares)
|
||
£16.6610
|
7
(matching shares)
|
||
d)
|
Aggregated
information
|
|
|
Aggregated
volume Price
|
14 Ordinary Shares
£16.6610
|
||
e)
|
Date
of the transaction
|
2024-03-11
|
|
f)
|
Place
of the transaction
|
London Stock Exchange (XLON)
|
|
GSK plc
|
|
(Registrant)
|
|
|
Date: March
13, 2024
|
|
|
|
|
By:/s/ VICTORIA
WHYTE
--------------------------
|
|
|
|
Victoria Whyte
|
|
Authorised
Signatory for and on
|
|
behalf
of GSK plc
|